Showing results (1-10 of 130) with videos related to
Sort By:
Pageof 13
Genome Medicine|December 31, 2024
The role of gut microbiota in the pathogenesis of diverticular disease: where are we now?Antonio Tursi, Alfredo PapaJournal of Clinical Gastroenterology|September 14, 2016
The Economic Burden of Diverticular DiseaseAlfredo Papa, Valerio PapaEuropean Journal of Gastroenterology & Hepatology|September 17, 2008
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic systemSilvio Danese, Alfredo PapaThe American Journal of Gastroenterology|August 23, 2020
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel DiseaseAlfredo Papa, Antonio Gasbarrini, Antonio TursiJournal of Integrative Neuroscience|December 30, 2024
The Neurophysiological Impact of Touch-Based Therapy: Insights and Clinical BenefitsMirjam Bonanno, Giuseppe Alfredo Papa, Rocco Salvatore CalabròExpert Opinion on Biological Therapy|February 7, 2024
Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studiesAntonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.The American Journal of Gastroenterology|June 24, 2003
Review article: inherited thrombophilia in inflammatory bowel diseaseAlfredo Papa, Silvio Danese, Antonino Grillo, et al.BMC Gastroenterology|March 25, 2020
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literatureValerio Papa, Maria Cristina Giustiniani, Loris Riccardo Lopetuso, et al.Journal of Crohn'S & Colitis|March 5, 2013
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel diseaseGiammarco Mocci, Manuela Marzo, Alfredo Papa, et al.Mini Reviews in Medicinal Chemistry|July 18, 2006
Biological therapies for inflammatory bowel disease: research drives clinicsSilvio Danese, Stefano Semeraro, Alessandro Armuzzi, et al.Pageof 13